As HR+ BC depends on E2-induced or constitutive ERα activation for the stimulation of tumor cell growth and proliferation, different ETs resulting in the inhibition of ERα signaling have proven to be effective in the treatment of HR+ BC patients in both adjuvant and advanced disease settings. The gene discussed is ESR1; the disease is neoplasm.